Published in Ann Surg Oncol on January 01, 2007
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol (2009) 2.88
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Gastrointestinal stromal tumor. World J Surg Oncol (2009) 2.05
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol (2011) 1.86
A gist of gastrointestinal stromal tumors: A review. World J Gastrointest Oncol (2013) 1.72
Gastrointestinal stromal tumor. J Gastrointest Oncol (2012) 1.57
The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors. Curr Opin Oncol (2008) 1.30
Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol (2012) 1.23
Modern treatment of gastric gastrointestinal stromal tumors. World J Gastroenterol (2012) 1.22
Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer (2011) 1.14
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer (2010) 1.08
Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol (2012) 1.00
Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med (2009) 0.97
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol (2012) 0.95
Surgical treatment of gastric gastrointestinal stromal tumor. J Gastric Cancer (2013) 0.94
Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today (2010) 0.91
Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy. World J Surg Oncol (2009) 0.90
Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective. World J Surg Oncol (2008) 0.90
Gastrointestinal stromal tumors (GISTs): an updated experience. Dig Dis Sci (2010) 0.89
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors. Gastrointest Cancer Res (2008) 0.88
Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol (2008) 0.88
Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors. Langenbecks Arch Surg (2007) 0.85
A case and literature review of complicated gastrointestinal stromal tumors. Gastroenterol Hepatol (N Y) (2008) 0.85
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor. Clinics (Sao Paulo) (2014) 0.84
Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol (2008) 0.83
Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol (2013) 0.83
Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol (2014) 0.82
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria. Wien Med Wochenschr (2013) 0.82
Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor. World J Gastroenterol (2009) 0.82
Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor. Int J Surg Case Rep (2014) 0.82
Gastrointestinal stromal tumors-diagnosis and management: a brief review. Ochsner J (2008) 0.81
Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor. J Korean Soc Coloproctol (2011) 0.81
Imatinib as preoperative therapy in Chinese patients with recurrent or metastatic GISTs. Chin J Cancer Res (2013) 0.80
Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours. Langenbecks Arch Surg (2008) 0.80
Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial. Int J Surg Oncol (2012) 0.80
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. BMC Cancer (2014) 0.79
Colorectal gastrointestinal stromal tumor. Tech Coloproctol (2010) 0.79
Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case. Surg Today (2010) 0.79
Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era? Langenbecks Arch Surg (2014) 0.79
Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST. Int J Clin Oncol (2010) 0.78
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. Am Surg (2014) 0.78
What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? Med Oncol (2013) 0.77
Gastrointestinal stromal tumor mesenchymal neoplasms: the offspring that choose the wrong path. J Multidiscip Healthc (2013) 0.77
Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs). Onco Targets Ther (2009) 0.76
Gastrointestinal stromal tumors: Recommendations on diagnosis, therapy and follow-up care in Austria. Wien Klin Wochenschr (2009) 0.76
Review. Gastroenterol Hepatol (N Y) (2008) 0.75
Preoperative imatinib treatment in patients with advanced gastrointestinal stromal tumors: patient experiences and systematic review of 563 patients. Int Surg (2015) 0.75
Clinicopathologic change of gastrointestinal stromal tumor after neoadjuvant imatinib followed by surgical resection. J Korean Surg Soc (2012) 0.75
A rare case of jejuno-ileal intussusception secondary to a gastrointestinal stromal tumour. J Surg Case Rep (2015) 0.75
Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery? Ann Surg Oncol (2007) 0.75
Using endoscopy to minimize the extent of resection in the management of giant GISTs of the stomach. Int J Surg Case Rep (2017) 0.75
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST). World J Surg Oncol (2017) 0.75
The predictive value of preoperative (18)F-fluorodeoxyglucose PET for postoperative recurrence in patients with localized primary gastrointestinal stromal tumour. Eur Radiol (2016) 0.75
Current research and treatment for gastrointestinal stromal tumors. World J Gastroenterol (2017) 0.75
Metastatic gastrointestinal stromal tumor: A regional cancer center experience of 44 cases. South Asian J Cancer (2017) 0.75
[Gastrointestinal stromal tumors: recommendations for diagnosis, treatment and aftercare in Austria]. Wien Med Wochenschr (2009) 0.75
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Risk-adjusted pathologic margin positivity rate as a quality indicator in rectal cancer surgery. J Clin Oncol (2014) 4.59
We should desist using RECIST, at least in GIST. J Clin Oncol (2007) 4.51
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 4.34
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol (2007) 4.05
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol (2004) 3.38
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Phenotype and genotype of pancreatic cancer cell lines. Pancreas (2010) 3.06
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med (2011) 2.91
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Soft tissue sarcomas. CA Cancer J Clin (2004) 2.65
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol (2009) 2.64
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol (2008) 2.51
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol (2008) 2.48
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol (2006) 2.42
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Imaging features of primary breast sarcoma. AJR Am J Roentgenol (2012) 2.26
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol (2006) 2.23
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer (2002) 2.21
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol (2003) 2.19
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol (2008) 2.17
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. J Control Release (2009) 2.16
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg (2011) 2.16
Modified Makuuchi incision for foregut procedures. Arch Surg (2010) 2.15